What is it?
Synthetic GH secretagogue, not a nootropic
3Ipamorelin is a synthetic pentapeptide growth hormone secretagogue and ghrelin-receptor agonist. It is sold online like a supplement, but the evidence and safety profile are closer to an endocrine-active research peptide than a normal nootropic ingredient.
Human evidence is endocrine and GI research, not cognition
2A healthy-volunteer PK/PD study showed growth-hormone release after IV infusion, and a phase 2 inpatient study tested IV ipamorelin for postoperative ileus. These studies do not show focus, memory, mood, anti-aging, fat-loss, bodybuilding, recovery, or wellness benefits.
Names, aliases and forms
Mechanisms of action
GH release is not a benefit claim
3Ipamorelin acts through GH secretagogue/ghrelin-like pathways and can produce a growth-hormone pulse. That mechanism is pharmacologically active, but it does not validate consumer claims about cognition, anti-aging, lean mass, recovery, or sleep.
Potential effects and evidence map
Ipamorelin has human pharmacology data showing growth-hormone release after infusion and a phase 2 postoperative-ileus trial, plus older animal work on GH-related outcomes. That is not a nootropic evidence base. It does not establish cognitive enhancement, anti-aging, recovery, fat loss, or sports-performance benefits for consumers. Current safety/regulatory context is central: FDA compounding materials identify significant safety concerns for ipamorelin acetate, especially injectable routes and peptide characterization, while WADA lists ipamorelin under prohibited GH secretagogues.
Ipamorelin is not an established wakefulness, stimulant, or mental-energy compound.
Ipamorelin is not established as a safe or effective performance, recovery, or bodybuilding agent for consumers.
No reliable human evidence supports anti-aging, longevity, or brain-health claims for Ipamorelin.
Typical dosages and timing
The healthy-volunteer PK/PD study used IV infusions of 4.21-140.45 nmol/kg over 15 minutes (about 0.2-7 mg for a hypothetical 70 kg adult). A separate postoperative-ileus trial administered 0.03 mg/kg intravenously twice daily for no more than 7 days. These are research exposures, not consumer dosing guides.
Timing & effect horizon
Human PK data report a short The time for blood levels to fall by half during the final elimination phase.Source and a GH peak after infusion, but that is endocrine pharmacology, not a nootropic onset or duration. Do not convert GH-release timing into a cognitive-use schedule.
Safety, side effects and risk profile
Ipamorelin is legally and sport-sensitive: WADA lists it as a prohibited GH secretagogue, and FDA compounding materials identify significant safety concerns for ipamorelin acetate.
Ipamorelin stimulates growth-hormone release, but direct long-term safety data are limited. GH/IGF-axis activity makes safety uncertain in endocrine and glucose-regulation contexts.
Direct drug-interaction evidence is limited. Safety implications are uncertain for people using diabetes drugs, hormone therapies, perioperative medicines, or complex regimens.
Long-term cardiometabolic safety has not been established, especially where GH/IGF-axis activity, fluid balance, blood pressure, or glucose regulation are relevant.
There are no adequate pregnancy, breastfeeding, pediatric, or fertility-care safety data for ipamorelin wellness use.
Consumer products may differ by salt form, purity, route, sterility, aggregation, impurities, dose, and undisclosed combinations.
FDA compounding materials identify potential safety risks for ipamorelin acetate, including immunogenicity concerns for injectable routes, aggregation or peptide-related impurities, unnatural amino acids, characterization complexity, and uncertainty for certain routes of administration.
Interactions and cautions
Direct interaction and long-term safety data are inadequate. People with diabetes, pituitary disease, cancer history, edema, sleep apnea, cardiovascular risk, hormone therapy, or complex medication regimens are populations with added uncertainty around GH/IGF-axis activity, not established wellness-use candidates.
Legal and regulatory status
As of 2026 in the United States, FDA lists ipamorelin acetate in Category 2 of its 503B compounding interim policy and identifies potential safety risks for certain compounded uses. This page does not determine the legal status of every ipamorelin product or jurisdiction.
Practical buying and quality notes
- If a marketplace listing lacks a legitimate medical indication, sterile manufacturing information, batch testing, identity confirmation, endotoxin testing, aggregation data, and legal route clarity, the product-quality risk is part of the safety profile, not just a shopping preference.6
- Stacking Ipamorelin with other GH secretagogues, anabolic agents, SARMs, insulin/glucose-lowering drugs, thyroid drugs, GLP-1 drugs, or recovery blends increases endocrine uncertainty and makes adverse effects harder to attribute.2
FAQ
Is Ipamorelin a nootropic?
2No. Ipamorelin has human GH-release pharmacology, but no reliable human evidence for focus, memory, mood, wakefulness, or cognitive enhancement.
Is Ipamorelin legal for athletes?
7No for WADA-governed sport. WADA's 2026 Prohibited List names ipamorelin under prohibited growth hormone secretagogues/mimetics. For athletes subject to those rules, it is prohibited at all times.
What dose of Ipamorelin is studied?
2In healthy male volunteers, IV infusions ranged from 4.21 to 140.45 nmol/kg over 15 minutes. A separate postoperative-ileus trial used 0.03 mg/kg IV twice daily for up to 7 days. These research regimens do not establish a consumer, subcutaneous, nasal, or oral dose.
Can Ipamorelin be used for anti-aging, recovery, or fat loss?
6The available evidence does not establish safe or effective consumer use for anti-aging, recovery, fat loss, bodybuilding, or wellness. Those claims are unproven and high risk.
References
- PubChem. Ipamorelin, CID 9831659. Accessed 2026-06-30.
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16(9):1416-1423.
- Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2015;30(4):515-522.
- Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone and IGF Research. 1999;9(2):106-113.
- U.S. Food and Drug Administration. Substances in Compounding that May Present Significant Safety Risks. Content current as of April 22, 2026. Accessed 2026-06-30.
- World Anti-Doping Agency. 2026 Prohibited List, S2 peptide hormones, growth factors, related substances and mimetics. Accessed 2026-06-30.